Skip to main content

Table 3 (abstract O17). Migraine disability assessment total score, month 6

From: 12th European Headache Federation Congress jointly with 32nd National Congress of the Italian Society for the Study of Headaches

 

LFEM

HFEM

 

Treatment

Baseline meana (SD)

N

LSM change from baseline ± SE

LSM change difference ± SE

p-valueb

Baseline meana (SD)

N

LSM change from baseline ± SE

LSM change difference ± SE

p-valueb

p-valuec

Placebo

25.7 (22.6)

241

-9.8 ± 1.4

  

36.9 (31.5)

483

-15.1 ± 1.2

   

Galca 120mg

25.1 (21.8)

126

-18.6 ± 1.8

-8.8 ± 1.9

<.001

35.3 (30.2)

254

-22.3 ± 1.5

-7.2 ± 1.5

<.001

.557

Galca 240mg

28.7 (24.6)

124

-15.9 ± 1.8

-6.2 ± 1.9

.001

37.2 (29.7)

241

-22.1 ± 1.5

-7.0 ± 1.6

<.001

.737

  1. Galca galcanezumab, N number of subjects who have a non-missing baseline value and at least one post-baseline value;
  2. aBased upon subjects with a non-missing baseline value; bp-value vs. placebo; cTreatment-by-subgroup interaction p-value vs. placebo
Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us